FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FLEMING WILLIAM H 		2. Issuer Name and Ticker or Trading Symbol

QUANTRX BIOMEDICAL CORP [ QTXB.OB ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

19190 SW 90TH AVE, #4690 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/25/2012
(Street)

TUALATIN, OR 97062
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/25/2012     J (1)    300000   A $0.06   (2) 1263034   D  
 
Common Stock                  1000   I   By Brother  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Warrant   $0.50                      (3) 7/24/2014   Common Stock   150000     150000   D  
 
Non Qualified Stock Options   $0.50                      (4) 7/30/2014   Common Stock   125000     125000   D  
 
Common Stock Warrant   $0.31                    1/15/2009   1/15/2014   Common Stock   110000     110000   D  
 
Incentive Stock Options   $0.85                      (5) 10/8/2017   Common Stock   50000     50000   D  
 
Incentive Stock Options   $1.60                      (6) 4/30/2016   Common Stock   100000     100000   D  
 

Explanation of Responses:
( 1)  Common stock issued in consideration for services rendered to QuantRx Biomedical Corporation.
( 2)  Price based on fair market value on the day of issuance.
( 3)  The options were granted on July 24, 2009 and fully vested with achievement of development milestone in November 2009.
( 4)  The options were granted on July 30, 2009 and half vested with achievement of development milestone in November 2009; remaining half vest upon achievement of development milestone which, as of August 9, 2012, has not yet been achieved.
( 5)  The options were granted October 8, 2007 and fully vested on October 8, 2008.
( 6)  The options were granted on April 3, 2006 and vest upon reaching negotiated sales of $10M.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FLEMING WILLIAM H
19190 SW 90TH AVE, #4690
TUALATIN, OR 97062 		X



Signatures
/s/ William H. Fleming 8/20/2012
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
QuantRx Biomedical (CE) (USOTC:QTXB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos QuantRx Biomedical (CE).
QuantRx Biomedical (CE) (USOTC:QTXB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos QuantRx Biomedical (CE).